Insider Cluster (2 insiders) ·Filed Sep 3, 2026

TRDA

Entrada Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed28d 13h ago
Insider cluster: 2 insiders, $515K total
Actionable Insight • Neutral

The selling is concentrated among large pre-IPO holders, not management, and the dollar amounts are small relative to market cap. Monitor for any upcoming catalyst (e.g., pipeline update or earnings) that could shift sentiment. The lack of C-suite selling suggests no insider bearish signal from management.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+5d
TRDA ▼ -5.16% at T+5d
NEUTRAL call ✗ call lost -5.16% · α vs SPY -4.01% · entry $7.17 → $6.80
Next anchor: T+20d due yesterday
Latest observation: T+17 -7.27% FF3 residual α
Entry anchored
Sep 2, 04:00 PM ET
via 1-min bar
T+1d
-0.56%
call -0.56% · α -0.17%
$7.13
settled 29d ago
T+5d
-5.16%
call -5.16% · α -4.01%
$6.80
settled 22d ago
T+20d
—
call — · α —
—
due yesterday
T+60d
—
call — · α —
—
in 8w

Price Chart

Loading chart...

Executive Summary

Two 10% owner entities (MPM BioVentures 2014 and 2018) sold a combined $515K in open-market shares over a week, representing ~0.18% of market cap. The CEO had a non-cash tax withholding transaction. This selling is part of a broader 30-day trend of $1.8M in insider sales, but the amounts are modest and involve only large holders, not C-suite executives.

Key Financial Metrics

Direction
selling
Total Value
$515.0K
Insiders
2

Key Facts

  • MPM BioVentures 2014 sold 29,088 shares at $7.06 ($205K) on 2026-09-01
  • MPM BioVentures 2018 sold 44,259 shares at $6.99 ($309K) on 2026-08-31
  • CEO Doshi Dipal had a tax withholding of 8,724 shares at $7.14 ($62K) on 2026-09-02 (non-cash)
  • Total insider selling over the past 30 days is $1.8M across 9 transactions
  • No C-suite open-market sales or purchases in this cluster

Financial Impact

Total open-market sales of $515K, representing 0.18% of $284M market cap

dilutionownership

Risk Factors

  • Continued distribution by large holders could create modest selling pressure
  • No insider buying to signal confidence in near-term prospects

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-TRDA-1788505541348
18 reports for TRDA
Performance horizon
50% Hit rate 2 of 4 directional calls best @ T+60▲ +58.52%May 4, 2026
Filters
Rows
Reports for TRDA — sortable, filterable
TypeNow
Sep 9, 2026
22d ago
Insider Cluster
BEARISH ★ 6/10
$6.42 $6.90▼ −7.48%▼ −7.98%$5.38 (+16.20%)
Sep 3, 2026
29d ago
Insider Cluster
NEUTRAL ★ 3/10
$7.17 $6.80▼ −5.16%▼ −4.01%$5.38 (−24.97%)
Aug 31, 2026
4w ago
Insider Cluster
NEUTRAL ★ 4/10
$7.07 $7.11▲ +0.57%▲ +0.48%$5.38 (−23.90%)
Aug 31, 2026
4w ago
Insider Cluster
NEUTRAL ★ 4/10
$7.07 $7.11▲ +0.57%▲ +0.48%$5.38 (−23.90%)
Aug 31, 2026
4w ago
Insider Cluster
NEUTRAL ★ 3/10
$7.07 $7.11▲ +0.57%▲ +0.48%$5.38 (−23.90%)
Aug 27, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$7.27 $7.17▼ −1.38%▼ −1.64%$5.38 (−26.00%)
Aug 10, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$7.04 $7.27▲ +3.27%▲ +3.67%$5.38 (−23.58%)
Aug 5, 2026
8w ago
8-K
NEUTRAL ★ 4/10
$7.06 $7.67▲ +8.64%▲ +8.29%$5.38 (−23.80%)
Aug 3, 2026
8w ago
Insider Cluster
NEUTRAL ★ 4/10
$7.24 $7.04▼ −2.76%▼ −2.66%$5.38 (−25.69%)
Jul 30, 2026
9w ago
144
BEARISH ★ 5/10
$6.79 $6.87▼ −1.18%▲ +2.33%$5.38 (+20.77%)
Showing 10 of 18

US Market Status

Market Closed — Opens Mon (65h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Sep 4, 2026